FeedbackFruits Launches the Enhanced Version of Their Team Based Learning Tool for Digitizing Collaboration

The new Team Based Learning tool aims to drive student engagement and collaboration through streamlining team-based learning across modalities. AMSTERDAM, NETHERLANDS / ACCESSWIRE / March 27, 2023 / FeedbackFruits has released the new Team Based Learning, an LMS-integrated tool designed to digitize and scale collaborative learning across all course sizes and modalities. Related Image Team Based […]

The new Team Based Learning tool aims to drive student engagement and collaboration through streamlining team-based learning across modalities.

AMSTERDAM, NETHERLANDS / ACCESSWIRE / March 27, 2023 / FeedbackFruits has released the new Team Based Learning, an LMS-integrated tool designed to digitize and scale collaborative learning across all course sizes and modalities.

Related Image

Team Based Learning supports and enhances the facilitation of the entire team-based learning (TBL) process, a collaborative learning approach that gives students the possibility to apply their knowledge to solve single or multiple problems.

The development of the tool was initiated in collaboration with Deakin University and IE Business School, where TBL is one of the prominent pedagogical approaches. Both institutions wanted to develop an easy-to-use, LMS-integrated tool to accommodate different elements of TBL. The initial version of the tool was launched to help automate the individual Readiness Assurance Test (iRAT) and team Readiness Assurance Test (tRAT). FeedbackFruits then continued to work with Deakin University over the past year to further expand the tool’s capacity to cover all the major steps of the TBL process.

The new Team Based Learning presents several functionalities that support and optimize each stage of the TBL process. With the ability to add engaging pre-work assignments, adjust activity timing, decide on group representatives, and configure peer evaluation steps, instructors can streamline a complete collaborative activity in any modality. At the same time, students enjoy a meaningful learning experience where collaboration, autonomy, and accountability are maintained.

Dr. Svetlana Stevanovic emphasized the tool’s capacity for facilitating meaningful collaborative activities:

“I used FeedbackFruits for my first-year unit. The unit has a team-based learning component where students are expected to collaborate to reach a consensus on a specific topic/research question. They are required to do some reading before the class. The unit runs online and in person. I used Team Based Learning to facilitate peer assessment and integrate the quiz into the studio. The enrollment process worked well and enabled students to participate in groups. Students were actively engaged and liked the classes.”

For Joost Verdoorn, Chief Product Officer of FeedbackFruits, the launch marks an exciting chapter in the company’s story of driving effective pedagogy: “With this release, we show that FeedbackFruits is dedicated to supporting innovative and proven teaching methods, allowing students worldwide to enjoy better and more meaningful learning experiences.”

Since its first iteration, the tool has been adopted at 39 institutions worldwide and helped faculties create 197 courses with 865 TBL activities.

About FeedbackFruits

FeedbackFruits is an EdTech scale-up based in Amsterdam whose mission is to drive student engagement while increasing teacher productivity. The platform encompasses a range of learning activities such as self & peer assessment, online discussion, and team-based learning. The company is currently supporting over 100 institutions worldwide with 90+ employees.

For more information, press only: marketing@feedbackfruits.com

Contact Information

Irmak Ozgenoglu
Marketing Manager
irmak@feedbackfruits.com

SOURCE: FeedbackFruits

Zoom announces the expansion of Zoom IQ, the smart companion that empowers collaboration and unlocks potential

Zoom uses OpenAI technologies to bolster a unique federated approach to AI based on flexibility SAN JOSE, Calif., March 27, 2023 (GLOBE NEWSWIRE) — Today at Enterprise Connect, Zoom Video Communications, Inc. (NASDAQ: ZM) announced the expansion of Zoom IQ, a smart companion that empowers collaboration and unlocks people’s potential by summarizing chat threads, organizing […]

Zoom uses OpenAI technologies to bolster a unique federated approach to AI based on flexibility

SAN JOSE, Calif., March 27, 2023 (GLOBE NEWSWIRE) — Today at Enterprise Connect, Zoom Video Communications, Inc. (NASDAQ: ZM) announced the expansion of Zoom IQ, a smart companion that empowers collaboration and unlocks people’s potential by summarizing chat threads, organizing ideas, drafting content for chats, emails, and whiteboard sessions, creating meeting agendas, and more. The company also announced it will use OpenAI to bolster its unique federated approach to AI based on flexibility.

Zoom’s federated approach to AI leverages its own proprietary AI models, those from leading AI companies– such as OpenAI –and select customers’ own models. With this flexibility to incorporate multiple types of models, Zoom’s goal is to provide the most value for its customers’ diverse needs. These models can also be customized to perform better for a customer, based on their vocabulary and requirements.

“Zoom has long built AI solutions into our products to empower customers to be more productive,” said Smita Hashim, chief product officer at Zoom. “We are excited to bring many more capabilities with new large language models. Our unique approach to AI will give customers the flexibility they want and help significantly improve collaboration and customer relations.”

In today’s work environment, workers find it increasingly difficult to balance workday priorities between emails, team chats, meetings, and project management tasks. Teams are also looking for ways to better co-create effectively in real-time. To help solve these challenges, Zoom IQ will have a host of new capabilities scheduled to release soon, including:

  • Zoom IQ chat compose: Zoom Team Chat users can soon use the compose feature to help compose messages based on conversational context in addition to changing message tone to customize suggested responses.
  • Zoom IQ email compose: Harnessing the power of Generative AI, users will get email draft suggestions in response to the conversational context from prior Zoom Meetings, Zoom Phone calls, and email threads. Available initially in Zoom IQ for Sales.
  • Zoom IQ meeting summary: Generate a summary, capture next steps, and share via Team Chat, Zoom Calendar, and email without recording the conversation, so those who didn’t attend will no longer have to sit through lengthy recordings.

Additionally at Enterprise Connect, Zoom is showcasing the following innovations to make teamwork more meaningful and strengthen customer relationships:

  • Zoom Huddles (formerly Zoom Spots) is a new video-enabled virtual coworking space designed to foster ad-hoc discussions and relationship building, to replicate the “working alongside” aspect of an open office and encourage free-form video-first conversations. Zoom Huddles is now available globally for customers to request early access by visiting the product page.
  • Intelligent Director uses multiple cameras in a Zoom Room to determine the best angle of the individuals in the room to display within the meeting. With high-quality, reliable video and voice, Intelligent Director also provides a best-in-class experience for remote participants. Available in beta soon.
  • Zoom Scheduler makes it easy to find the perfect time for meetings by sharing the host’s availability so others (even external participants) can conveniently book appointments. Zoom Scheduler reduces the back-and-forth hassle of manual scheduling by placing a meeting on the host’s calendar with a Zoom Meetings link already included, saving both participants time. Zoom Scheduler works seamlessly with Zoom Meetings and Zoom Mail and Calendar, and integrates with Google Calendar and Microsoft 365, so hosts can use their preferred calendar.

Additional Resources:

About Zoom
Zoom is an all-in-one intelligent collaboration platform that makes connecting easier, more immersive, and more dynamic for businesses and individuals. Zoom technology puts people at the center, enabling meaningful connections, facilitating modern collaboration, and driving human innovation through solutions like team chat, phone, meetings, omnichannel cloud contact center, smart recordings, whiteboard, and more, in one offering. Founded in 2011, Zoom is publicly traded (NASDAQ:ZM) and headquartered in San Jose, California. Get more info at zoom.com.

Zoom Public Relations
Beth McLaughlin
press@zoom.us

GlobeNewswire Distribution ID 8795878

‫وزارة الصحة الكندية تمنح تصريحًا لشركة bioLytical Laboratories Inc. لاختبار الأجسام المضادة INSTI® Multiplex HIV-1/2 Syphilis

أعلنت شركة bioLytical Laboratories Inc. اليوم أنها أطلقت اختبار الأجسام المضادة INSTI® Multiplex HIV-1/2 Syphilis وأنه أصبح متاحًا للاستخدام من قبل المتخصصين في كندا. حصلت bioLytical على تصريح من وزارة الصحة الكندية لطرح اختبار الأجسام المضادة INSTI® Multiplex HIV-1/2 Syphilis للبيع في جميع أنحاء كندا لاستخدامه من قبل المتخصصين في مرافق الرعاية الصحية يقلل الاختبار من […]

أعلنت شركة bioLytical Laboratories Inc. اليوم أنها أطلقت اختبار الأجسام المضادة INSTI® Multiplex HIV-1/2 Syphilis وأنه أصبح متاحًا للاستخدام من قبل المتخصصين في كندا.

  • حصلت bioLytical على تصريح من وزارة الصحة الكندية لطرح اختبار الأجسام المضادة INSTI® Multiplex HIV-1/2 Syphilis للبيع في جميع أنحاء كندا لاستخدامه من قبل المتخصصين في مرافق الرعاية الصحية
  • يقلل الاختبار من القلق لدى المرضى حيال إجراء الاختبارات حيث يتيح لأخصائيي الرعاية الصحية اختبار المزيد من الأشخاص في وقت أقل من خلال تقديم النتائج بخصوص اثنتين من العدوى باستخدام عينة واحدة فقط
  • الاختبار سهل الحمل ويمكن إجراؤه في العديد من الأماكن مع نتائج سهلة الفهم
  • وفي إطار المراجعة التي أجرتها وزارة الصحة الكندية ومنحها التصريح، تضمَّنت الوثائق المقدمة بيانات سريرية مستقاة من دراسة (PoSH) التي استغرقت عامين وأُجريت بقيادة باحثين في جامعة ألبرتا ومستشفى سانت مايكل وهو أحد المواقع التابعة لـ Unity Health Toronto
  • أظهر اختبار الأداء في الدراسات السريرية دقة عالية، مع حساسية وتخصصية رائدتين في الصناعة
  • نظام الجودة في bioLytical هو (MDSAP): حاصل على شهادة الجودة أيزو ISO 13485

ريتشموند، كولومبيا البريطانية، 27 مارس/آذار 2023 (GLOBE NEWSWIRE) – أعلنت شركة bioLytical Laboratories Inc. (“bioLytical”)، الشركة العالمية الرائدة في مجال التشخيص الطبي السريع في المختبرات، اليوم حصولها على تصريح من وزارة الصحة الكندية بخصوص اختبار الأجسام المضادة INSTI® Multiplex HIV-1/2 Syphilis لديها، ما يسمح بدخولها الفوري إلى السوق الكندية. بالإضافة إلى ذلك، تعمل bioLytical على تقديم إصدار اختبار ذاتي لضمان إمكانية حصول الكنديين من جميع الفئات السكانية على الاختبارات المنتظمة والمبكرة لكلتا العدوى، في أي وقت وفي أي مكان يكون فيه أكثر ملاءمة لهم.

صرَّح Rob Mackie، الرئيس التنفيذي لشركة bioLytical، قائلًا “أنا فخور بقيادة فريق من الأشخاص المتفانين والمبدعين الذين يوسعون آفاق ما هو ممكن على الدوام”، وأردف قائلًا “إن التزامنا المستمر بتحقيق التميز هو ما مكننا من الوصول إلى هذا الإنجاز الرائع الذي سيساعد الكنديين من جميع الفئات السكانية على إجراء الاختبارات المبكرة في مختلف الأماكن.”

ولكونها شركة رائدة معروفة في ميدان اختبارات فيروس نقص المناعة البشرية على مستوى العالم بفضل اختبار الأجسام المضادة المبتكر INSTI® HIV-1/2 المصرح به من قبل وزارة الصحة الكندية للاستخدام من قبل المتخصصين ولأغراض الاختبار الذاتي، استفادت شركة bioLytical من تقنية INSTI® لابتكار اختبار الأجسام المضادة INSTI® Multiplex HIV-1/2 Syphilis الذي تمت الموافقة عليه لأول مرة ويجري استخدامه في أوروبا وأفريقيا منذ عام 2016.

الهدف من الاختبار هو اكتشاف كل من الأجسام المضادة لفيروس نقص المناعة البشرية-1/2 والزهري من خلال عينة واحدة باستخدام طريقة وخز الإصبع البسيطة للحصول على نتائج موثوقة في دقيقة واحدة أو أقل. تتيح INSTI® لأخصائي الرعاية الصحية إجراء الاختبار في مختلف البيئات بفضل قابلية نقله وسهولة استخدامه، الأمر الذي يوفر خيارات مرنة للأشخاص الذين يواجهون صعوبة في الحصول على خدمات الرعاية الصحية.

وفي إطار المراجعة التي أجرتها وزارة الصحة الكندية ومنحها التصريح فيما بعد، تضمنت الوثائق المقدمة دراسة اختبار نقطة الرعاية لمرض الزهري وفيروس نقص المناعة البشرية (PoSH) التي أجريت في الفترة ما بين أغسطس 2020 وفبراير 2022. أظهرت الدراسة – التي أُجريت بقيادة باحثين في جامعة ألبرتا ومستشفى سانت مايكل وهو أحد المواقع التابعة لـUnity Health Toronto، أهمية الاختبارات المنتظمة والمتكررة كوسيلة لتسهيل وصول المرضى إلى خدمات الرعاية. وبفضل النتائج الفورية التي توفرها منصة INSTI® المبتكرة، فقد تم توصيل الأشخاص الذين ثبتت إصابتهم بفيروس نقص المناعة البشرية بخدمات الرعاية أو إعادة إيصالهم بها؛ وأما الأشخاص الذين ثبتت إصابتهم بمرض الزهري النشط، فقد تلقى غالبيتهم (87.4٪) العلاج على الفور بعد نتائج اختبار نقطة الرعاية، وتلقى باقي المشاركين العلاج غضون أربعة أيام في المتوسط.

يُعد مرض الزهري من المشكلات الصحية الخطيرة التي يمكن أن تؤدي إلى آثار طويلة المدى على الصحة إذا تُركت دون علاج. تشهد كندا حاليًا معدلات غير مسبوقة للإصابة بمرض الزهري، حيث ارتفعت بنسبة 166٪ من عام 2017 إلى عام 2021 على الصعيد الوطني. وارتفعت معدلات الإصابة في جميع الفئات السكانية، مع زيادة الإصابات الجديدة بنسبة 20٪ بين عامي 2020 و2021 في ظل انخفاض الوصول إلى خدمات العدوى المنقولة جنسياً والعدوى المنقولة عن طريق الدم أثناء جائحة كورونا. علاوة على ذلك، زادت حالات الإصابة بمرض الزهري الخلقي بنسبة 1271٪ خلال نفس الفترة، مما يسبب أيضًا قلقًا متزايدًا.

تشكِّل الإصابة بمرض الزهري وفيروس نقص المناعة البشرية في آن واحد مصدر قلق متزايد بالنظر إلى أن هناك ما يقدر بـ 62,790 شخصًا مصابًا بفيروس نقص المناعة البشرية في كندا وأن هناك ما يقرب من 1,520 حالة إصابة جديدة بفيروس نقص المناعة البشرية كل عام. وفي حين أن كلتا العدوتين يمكن أن تصيبا أي شخص، فإن الإصابة بعدوى منقولة جنسيًا مثل مرض الزهري تزيد من خطر الإصابة بفيروس نقص المناعة البشرية، فضلًا عن أنها تزيد من خطر انتقال فيروس نقص المناعة البشرية لدى المصابين بهذا الفيروس. من جانب آخر، يمكن لفيروس نقص المناعة البشرية وغيره من العدوى المنقولة جنسيًا أن يتسلل إلى الجسم من خلال القروح التي يسببها مرض الزهري.

ويعتبر الاختبار السريع ضروريًا للقضاء على مرض الزهري وفيروس نقص المناعة البشرية باعتبارهما من المخاطر التي تهدد على الصحة العامة. يتيح إجراء الاختبار بصورة منتظمة ومبكرة للمتخصصين في المجال الطبي تقديم التدخلات المبكرة عن طريق إيصال المرضى بخدمات الرعاية والدعم على وجه السرعة، والحد من انتقال العدوى، وزيادة الوعي بطرق الوقاية.

هذا ويمكن علاج مرض الزهري عادةً بحقنة بسيطة من الدواء إذا تم تشخيصه في غضون عام من الإصابة. وعلى الجانب الآخر، شهد علاج فيروس نقص المناعة البشرية تقدمًا ملحوظًا منذ اكتشاف الفيروس قبل أكثر من 40 عامًا، ما مكّن الأشخاص المصابين بفيروس نقص المناعة البشرية من العيش حياة طويلة وصحية أثناء تلقي العلاج. إن ابتكار اختبار يمكنه اكتشاف كلتا العدوتين من عينة واحدة يساعد على ضمان وصول الكنديين إلى الرعاية بشكل سريع ومنصف. يعتبر اختبار الأجسام المضادة INSTI® Multiplex HIV-1/2 Syphilis طريقة مبتكرة وفعالة لتوسيع نطاق الوصول إلى الاختبارات المبكرة والمنتظمة للعدوى المنقولة جنسياً والعدوى المنقولة عن طريق الدم في كندا.

صرح Mackie قائلًا “هناك حاجة ملحة لإجراء اختبار تشخيصي سريع وموثوق في ضوء ظهور مرض الزهري في كندا، فضلًا عن الزيادة المقلقة في الإصابة بمرض الزهري الخلقي”. وأضاف قائلًا “من خلال ابتكار اختبار دقيق للغاية ومبتكر مدته دقيقة واحدة، تتيح INSTI® للكنديين معرفة حالة إصابتهم باثنتين من العدوى بقطرة دم واحدة، وهو ما ساعد المزيد من الكنديين على إجراء الاختبار، ومعرفة حالة إصابتهم، والحصول على الرعاية.”

ستنتج شركة bioLytical اختبار الأجسام المضادة INSTI® Multiplex HIV-1/2 Syphilis في برنامج التدقيق الفردي للأجهزة الطبية (MDSAP) الخاص بها: وهي منشأة حاصلة على شهادة الجودة أيزو ISO 13485 في كولومبيا البريطانية للبيع والتوزيع في جميع أنحاء كندا. بصفتها شركة عالمية رائدة في تشخيص الأمراض المعدية فائقة السرعة، تعمل bioLytical على ضمان توفر مجموعات الاختبار لدينا للكنديين ليتمكنوا من معرفة حالة إصابتهم.

هذا وتعتبر شركة bioLytical Laboratories Inc.‎ شركة قطاع خاص كندية تعمل في مجالات البحث والتطوير والتسويق التجاري للتشخيصات الطبية السريعة في المختبرات، باستخدام منصتها التكنولوجية INSTI®‎ وخط الفحوص السريعة iStatis. وفازت bioLytical بالعديد من الجوائز المحلية والصناعية، بما في ذلك مُصدِّر العام في 2019 في بريتش كولومبيا. لقد حزنا لقب الشركة التقنية الطبية النامية لهذا العام في مجال علوم الحياة في بريتش كولومبيا، كما وشكّلنا مادة إعلامية دسمة بصفتنا أسرع الشركات نموًا في بريتيش كولومبيا لست أعوام، ومن ذلك دخولنا في قائمة الشركات الأسرع نموًا في عام 2020 لصحيفة جلوب أنجد ميل. وقد انتقلت bioLytical إلى مقر أحدث وأكبر بكثير، في ريتشموند، كولومبيا البريطانية، في عام 2020 لاستيعاب النمو الكبير الذي حققه فريقنا. من خلال تقديم نتائج دقيقة في دقيقة واحدة أو أقل، تشتمل مجموعة INSTI® على اختبار الأجسام المضادة INSTI® HIV-1/HIV-2، واختبار INSTI® Multiplex HIV Syphilis، واختبار INSTI® HIV الذاتي، واختبار الأجسام المضادة لكوفيد-19 INSTI®‎، واختبار الأجسام المضادة INSTI® HCV. تطرح bioLytical منتجاتها للبيع في أوروبا وأمريكا الشمالية وأمريكا الجنوبية وأفريقيا وآسيا. وقد أطلقت bioLytical منصة iStatis في عام 2022، وهي منصتها الجديدة لاختبار الفحوص السريعة لتوفير إتاحة أكبر للاختبار في جميع أنحاء العالم.

ومن خلال تقديم نتائج دقيقة في الوقت الفعلي، تقدم INSTI® وiStatis نتائج مهمة للمختصين الطبيين والمرضى ومؤسسات الصحة العامة في جميع أنحاء العالم، كما وتعتبر شريكًا مهمًا في معالجة بعض أكثر تحديات الرعاية الصحية خطورة في العالم. تفضل بزيارة www.istatis.com و www.insti.com و www.biolytical.com للاطلاع على مزيد من المعلومات.

المراجع

CATIE: https://www.catie.ca/syphilis-0

PHAC: https://www.canada.ca/en/public-health/services/reports-publications/canada-communicable-disease-report-ccdr/monthly-issue/2022-48/issue-11-12-november-december-2022/infectious-congenital-syphilis-canada-2021.html PHAC: https://www.canada.ca/en/public-health/services/publications/diseases-conditions/estimates-hiv-incidence-prevalence-canada-meeting-90-90-90-targets-2020.html

تتوفر الصورة المرفقة بهذا الإعلان عبر الرابط https://prdesk.globenewswire.com/api/ResourceLibraryFile/DownloadFile?source=pnr&Id=4adaf035-89ca-428d-a01d-9bf5c3f05e4b

جهة الاتصال الإعلامي:

Stephanie Ritchie، أخصائية الاتصالات في شركة bioLytical

press@biolytical.com

‎+1-778-238-9340

GlobeNewswire Distribution ID 3511006

LeddarTech Releases LeddarVision Premium Surround, Its Latest Low-Level Fusion and Perception Product, to Support Automotive Level 2/2+ ADAS Applications

LeddarTech’s award-winning LeddarVision solution QUEBEC CITY, March 27, 2023 (GLOBE NEWSWIRE) — LeddarTech®, a global leader in providing the most flexible, robust and accurate ADAS and AD software technology, announces its third product launch since December with the LeddarVision™ Surround (LVS-2+). This product is a comprehensive fusion and perception software stack to support premium surround-view […]

LeddarTech’s award-winning LeddarVision solution

LeddarVision technology recognized at Tech.AD USA and CES 2023

QUEBEC CITY, March 27, 2023 (GLOBE NEWSWIRE) — LeddarTech®, a global leader in providing the most flexible, robust and accurate ADAS and AD software technology, announces its third product launch since December with the LeddarVision™ Surround (LVS-2+). This product is a comprehensive fusion and perception software stack to support premium surround-view L2/L2+ ADAS highway assistance and 5-star NCAP 2025/GSR 2022 safety applications.

LeddarVision Surround (LVS-2+) is the latest low-level sensor fusion and perception product built on LeddarTech’s award-winning LeddarVision software. The LVS-2+ expands the company’s current product offering of the LeddarVision Front-Entry LVF-E and Front-High LVF-H. These products target entry- to premium-level ADAS applications.

The LVS-2+ efficiently extends the LVF front-view product family from a one-camera plus two to five-radar (1V2R-1V5R) sensor configuration to a five-camera plus five-radar (5V5R) configuration. This enhanced configuration supports ADAS functions such as traffic jam and highway assist applications, enabling automated lane changes, overtaking and extended speed range adaptive cruise control.

High-Performance and Cost-Effective

  • LeddarVision’s low-level fusion (LLF) technology pushes the performance envelope, extending the effective range of the sensors.
  • Low-level fusion optimally combines camera and radar modalities, achieving a high-performance system with reduced requirements per modality at a lower total sensing cost.
  • Superior accuracy in object separation and longitudinal position measurement on highways enables higher-performing adaptive cruise control implementation.
  • L2/L2+ highway assist, including adaptive cruise control up to 160 km/h, lane centering control, active lane change assist, traffic jam assist and highway assist (including auto-lane change support).

Safety

  • LVS-2+ addresses 5-star NCAP 2025/GSR 2022 safety applications.
  • Includes a built-in redundancy feature to accommodate sensor failures, degradations and conflicts.
  • LVS-2+ supports global scene attributes detection for operational design domain (ODD) analysis, sensor coverage and health monitoring features.

Flexible and Scalable

  • A comprehensive surround-view fusion and perception software platform that supports entry-level to premium ADAS highway assist Level 2/2+ applications.

Samples available: Contact LeddarTech for “A” samples of the LVS-2+ and “A” samples of the LVF-E and LVF-H products. LVS-2+ “B” sample availability is planned for late Q3 2023.

“LeddarTech is committed to supporting automotive Tier 1-2 suppliers and OEMs with software solutions and products that support enhanced safety features and lower overall development costs,” stated the company’s CEO, Charles Boulanger. “In December, we released our LVF products for entry-level to premium ADAS safety and highway assistance L2/L2+ applications, and in keeping with our commitment to continual product development, our newest product LeddarVision Surround (LVS-2+) further increases our software offering to our customers, with products that solve more safety issues with a scalable low-level fusion and perception software stack that offers higher performance at a lower cost,” Mr. Boulanger concluded.

LeddarTech launches the LVS-2+ officially at Automotive Tech.AD Berlin on March 27, 2023.

About LeddarTech

LeddarTech, a global software company founded in 2007, develops and provides comprehensive perception software solutions that enable the deployment of ADAS and autonomous driving applications. LeddarTech’s automotive-grade software applies advanced AI and computer vision algorithms to generate highly accurate 3D models of the environment, allowing for better decision making and safer navigation. This high-performance, scalable, cost-effective technology is leveraged by OEMs and Tier 1-2 suppliers to efficiently implement automotive and off-road vehicle ADAS solutions.

LeddarTech is responsible for several remote-sensing innovations, with over 150 patents granted or applied for that enhance ADAS and AD capabilities. Better awareness around vehicle is critical in making global mobility safer, more efficient, sustainable and affordable: this is what drives LeddarTech to become the most widely adopted sensor fusion and perception software solution.

Additional information about LeddarTech is accessible at www.leddartech.com and on LinkedIn, Twitter, Facebook and YouTube.

Contact:
Daniel Aitken, Vice-President, Global Marketing, Communications and Investor Relations, LeddarTech Inc.
Tel.: + 1-418-653-9000 ext. 232 daniel.aitken@leddartech.com

Investor relations contact and website: InvestorRelations@leddartech.com
https://investors.leddartech.com/

Leddar, LeddarTech, LeddarVision, LeddarSP, VAYADrive, VayaVision and related logos are trademarks or registered trademarks of LeddarTech Inc. and its subsidiaries. All other brands, product names and marks are or may be trademarks or registered trademarks used to identify products or services of their respective owners.

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/b7f20647-203a-42b4-b015-cedc2086ded5

GlobeNewswire Distribution ID 8793884

ROSEN, NATIONAL TRIAL LAWYERS, Encourages SVB Financial Group Investors to Secure Counsel Before Important Deadline in Securities Class Action Filed by the Firm – SIVB

NEW YORK, March 26, 2023 (GLOBE NEWSWIRE) — WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of SVB Financial Group (NASDAQ: SIVB) between June 16, 2021 and March 10, 2023, inclusive (the “Class Period”), of the important May 12, 2023 lead plaintiff deadline in the securities class action […]

NEW YORK, March 26, 2023 (GLOBE NEWSWIRE) —

WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of SVB Financial Group (NASDAQ: SIVB) between June 16, 2021 and March 10, 2023, inclusive (the “Class Period”), of the important May 12, 2023 lead plaintiff deadline in the securities class action commenced by the Firm.

SO WHAT: If you purchased SVB securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

WHAT TO DO NEXT: To join the SVB class action, go to https://rosenlegal.com/submit-form/?case_id=12882 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email pkim@rosenlegal.com or cases@rosenlegal.com for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than May 12, 2023. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources or any meaningful peer recognition. Many of these firms do not actually litigate securities class actions, but are merely middlemen that refer clients or partner with law firms that actually litigate the cases. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs’ Bar. Many of the firm’s attorneys have been recognized by Lawdragon and Super Lawyers.

DETAILS OF THE CASE: According to the lawsuit, defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose that: (1) the Company failed to disclose to investors the risks presented by impending rising interest rates; (2) the Company failed to disclose to investors that, in an environment with high interest rates, it would be worse off than banks that did not cater to tech startups and venture capital-backed companies; (3) the Company failed to disclose that, if its investments were negatively affected by rising interest rates, it was particularly susceptible to a bank run; (4) as a result, defendants’ public statements were materially false and/or misleading at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.

To join the SVB class action, go to https://rosenlegal.com/submit-form/?case_id=12882 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email pkim@rosenlegal.com or cases@rosenlegal.com for information on the class action.

No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor’s ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Attorney Advertising. Prior results do not guarantee a similar outcome.

——————————

Contact Information:

Laurence Rosen, Esq.
Phillip Kim, Esq.
The Rosen Law Firm, P.A.
275 Madison Avenue, 40th Floor
New York, NY 10016
Tel: (212) 686-1060
Toll Free: (866) 767-3653
Fax: (212) 202-3827
lrosen@rosenlegal.com
pkim@rosenlegal.com
cases@rosenlegal.com
www.rosenlegal.com

GlobeNewswire Distribution ID 8795226

RVYL FINAL DEADLINE NOTICE: ROSEN, TRUSTED INVESTOR COUNSEL, Encourages RYVYL Inc. f/k/a Greenbox POS Investors to Secure Counsel Before Important April 3 Deadline in Securities Class Action Filed by the Firm – RVYL, GBOX

NEW YORK, March 26, 2023 (GLOBE NEWSWIRE) — WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Ryvyl Inc. f/k/a Greenbox POS (NASDAQ: RVYL, GBOX): (i) pursuant and/or traceable to the registration statement and prospectus issued in connection with the Company’s January 29, 2021 public offering (the “Offering”); […]

NEW YORK, March 26, 2023 (GLOBE NEWSWIRE) — WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Ryvyl Inc. f/k/a Greenbox POS (NASDAQ: RVYL, GBOX): (i) pursuant and/or traceable to the registration statement and prospectus issued in connection with the Company’s January 29, 2021 public offering (the “Offering”); and/or (ii) between January 29, 2021 and January 20, 2023, both dates inclusive (the “Class Period”), of the April 3, 2023 lead plaintiff deadline in the securities class action commenced by the Firm.

SO WHAT: If you purchased Ryvyl securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

WHAT TO DO NEXT: To join the Ryvyl class action, go to https://rosenlegal.com/submit-form/?case_id=11425 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email pkim@rosenlegal.com or cases@rosenlegal.com for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than April 3, 2023. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually litigate securities class actions, but are merely middlemen that refer clients or partner with law firms that actually litigate the cases. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs’ Bar. Many of the firm’s attorneys have been recognized by Lawdragon and Super Lawyers.

DETAILS OF THE CASE: According to the lawsuit, the Registration Statement was false and/or misleading and/or failed to disclose that: (1) the Company would restate certain financials; (2) the Company’s internal controls were inadequate; (3) the Company downplayed and obfuscated its internal controls issues; and (4) as a result, the Registration Statement was materially false and/or misleading at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.

To join the Ryvyl class action, go to https://rosenlegal.com/submit-form/?case_id=11425 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email pkim@rosenlegal.com or cases@rosenlegal.com for information on the class action.

No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor’s ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Attorney Advertising. Prior results do not guarantee a similar outcome.

——————————

Contact Information:

Laurence Rosen, Esq.
Phillip Kim, Esq.
The Rosen Law Firm, P.A.
275 Madison Avenue, 40th Floor
New York, NY 10016
Tel: (212) 686-1060
Toll Free: (866) 767-3653
Fax: (212) 202-3827
lrosen@rosenlegal.com
pkim@rosenlegal.com
cases@rosenlegal.com
www.rosenlegal.com

GlobeNewswire Distribution ID 8795216